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Results: A total of 18 pts were treated. All had prior platinum and 16 
pts had prior taxanes; 15 were platinum-refractory (i.e., progressed on 
treatment or within 3 months after treatment) and 14 were taxane-re-
fractory. The ﬁrst group of 12 pts were randomized; 6 each to Arm A 
and Arm B. Toxicity was mild to moderate. In Arm A (docetaxel 75 mg/
m2 + suramin), 3 pts had neutropenic fevers. Therefore, the docetaxel 
dose was reduced by 25%, and 6 additional pts were treated with 56 
mg/m2 docetaxel + suramin. No febrile neutropenia was observed at 
the lower docetaxel dose or for pts treated with gemcitabine + suramin. 
Among the 18 pts, 4 received only gemcitabine + suramin, and 14 
received docetaxel + suramin (with or without rotating to gemcitabine 
+ suramin). Pharmacokinetic analysis revealed that the plasma suramin 
concentrations were <50 μM in all of the treatments and were >10 μM 
in 87% of all treatments. The following table summarizes the response 
and survival data. The group that received docetaxel + suramin ap-
peared to have more favorable response and survival compared to the 
group that received only gemcitabine + suramin. 
Group (n)
%  
platinum- 
refractory
% 
taxane-
refractory
Median # 
of cycles Best response, %
PFS 
Months 
MST, 
Months 
(95% CI)
1 yr 
survival 
%
    PD ORR SD    
Sur + Gem 
only (4) 100 75 2.5 50.0 0.0383 50.0
3.2  
(1.9, 5.3)
4.1  
(2.0, 6.9)  
Sur + Doc (5) & 
Sur + Doc/Gem 
(9)
79 79 5 23.1 15.4 61.5 4.0  (2.4, 5.3)
11.8  
(5.4, 14.0) 50.0
Overall (18) 83 78 3.5 27.8 11.1 61.1 3.9  (2.4, 5.0)
9.1  
(4.1, 12.7) 38.9
Conclusions: Combinations of nontoxic suramin with docetaxel 
56 mg/m2 or gemcitabine 1250 mg/m2 is well tolerated. Suramin + 
docetaxel (56 mg/m2) may have activity in paclitaxel/platinum-pretreat-
ed/refractory NSCLC patients. Supported in part by NCI UOlCA76576 
and Sanoﬁ-Aventis.
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Background: Pulmonary pleomorphic carcinoma is a rare tumor of 
the lung which is believed to spread at an early stage and to have an 
aggressive clinical course. The efﬁcacy of chemotherapy for advanced 
pulmonary pleomorphic carcinoma has not been deﬁned. The objective 
of this study was to evaluate the efﬁcacy of palliative chemotherapy for 
pulmonary pleomorphic carcinoma.
Methods: Thirteen consecutive patients who received palliative 
chemotherapy for advanced pulmonary pleomorphic carcinoma were 
investigated. All 13 patients were treated using chemotherapy regimens 
known to be active for the treatment of advanced non-small cell lung 
cancer (NSCLC).
Results: Of 13 patients, Nine were male (78.8%) and four were female 
(21.2%), and median age was 59 years with a range of 50 to 77 years.
Eleven patients (85%) had progressive disease and two (15%) had 
stable disease after ﬁrst-line chemotherapy. No patient achieved an 
objective response (objective response rate, 0%; 95% conﬁdence inter-
val, 0-23%). Eight of thirteen patients were given second-line chemo-
therapy, and all had progressive disease after second-line chemotherapy 
(objective response rate, 0%; 95% CI, 0-32%). Median overall survival 
from the initiation of ﬁrst-line palliative chemotherapy was only 4 
months (range, 2-12) with a median follow up of 16 months.
Conclusion: Advanced pulmonary pleomorphic carcinoma showed 
poor response to chemotherapy regimens that provide active treatment 
for NSCLC. Novel treatment approaches are required for pulmonary 
pleomorphic carcinoma.
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Background: A weekly administration of paclitaxel has demonstrated 
a sustained efﬁcacy and more favorable toxicity proﬁle than a 3-
weekly administration. The present study was conducted to evaluate 
the efﬁcacy and safety of a combination regimen of weekly paclitaxel 
plus carboplatin in patients with advanced non small cell lung cancer 
(NSCLC). In addition, we examined 6 polymorphism of ERCC1, 
XPD and XRCC1 and whether these polymorphism have an effect on 
response and survival in advanced NSCLC patients who have received 
this regimen. 
Methods: Patients with previously untreated measurable advanced 
NSCLC received intravenous paclitaxel 90 mg/m2 on days 1 and 8 
plus carboplatin AUC 6 on day 1 based on a 3-week cycle. We used 
polymerase chain reaction-restriction fragment length polymor-
phism to evaluate genetic polymorphism of the ERCC1 (Asn118Asn, 
Asp312Asn), XPD (Asp312Aap, Lys751Gln) and XRCC1 (Arg194Trp, 
Arg280His, Arg399Gln). 
Results: From August 2005 to date, 32 patients were enrolled in this 
study. An overall response rate was 43.7%. The estimated median time 
to progression and median overall survival was 5.4 months and 11.3 
months, respectively. Grade 3 neutropenia occurred in 7 patients, grade 
4 neutropenia in 2 patients and febrile neutropenia was observed in 1 
patient. Non hematologic toxicities were mild. There were no treat-
ment-related deaths. There was no relationship between polymorphisms 
of DNA repair gene and response rate.
Conclusions: A weekly paclitaxel and carboplatin combination was 
found to be well-tolerated and effective in patients with advanced 
NSCLC. Final data, including relationship between polymorphisms of 
DNA repair gene and survival, will be presented at the meeting. 
